{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:49:59Z","timestamp":1790664599946,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601428"],"award-info":[{"award-number":["81601428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to suppress acute myeloid leukemia (AML). However, the role of DDX5 remains elusive in APL. Here a DDX5-targeting fully human monoclonal autoantibody named after 2F5 was prepared. It is demonstrated that 2F5 selectively inhibited APL cell proliferation without toxicity to normal neutrophil and tissues. Moreover, 2F5 was confirmed to induce G0\/G1 phase arrest in APL cells, and promote APL cell differentiation combined with decreased DDX5 expression and increased reactive oxygen species (ROS) production. Knockdown of DDX5 by siRNA also inhibited proliferation, promoted cell differentiation and enhanced ROS production in APL cells. However, the ROS inhibitor reversed the effects of 2F5 on DDX5 and ROS in APL cells. Thus, we conclude that DDX5-targeting 2F5 inhibits APL cell proliferation, and promotes cell differentiation via induction of ROS. 2F5 showed the therapeutic value of fully human monoclonal autoantibody in APL, which provides a novel and valid approach for treatment of relapse\/refractory APL.<\/jats:p>","DOI":"10.1038\/s41419-020-02759-5","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T06:04:16Z","timestamp":1595225056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["DDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production"],"prefix":"10.1038","volume":"11","author":[{"given":"Jing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qiu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Xiu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hua","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Ji","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Hong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ben","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"2759_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nm.3441","volume":"20","author":"V Ablain","year":"2014","unstructured":"Ablain, V. et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat. Med. 20, 167\u2013174 (2014).","journal-title":"Nat. Med."},{"key":"2759_CR2","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1073\/pnas.0712365105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl Acad. Sci. USA 105, 4826\u20134831 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2759_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1056\/NEJMc1409040","volume":"371","author":"J Lehmann-Che","year":"2014","unstructured":"Lehmann-Che, J., Bally, C. & de Th\u00e9, H. Resistance to therapy in acute promyelocytic leukemia. N. Engl. J. Med. 371, 1170\u20131172 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2759_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1517\/14656566.2012.677436","volume":"13","author":"M Breccia","year":"2012","unstructured":"Breccia, M. & Lo-Coco, F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert. Opin. Pharm. 13, 1031\u20131043 (2012).","journal-title":"Expert. Opin. Pharm."},{"key":"2759_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111\u2013121 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2759_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/MOH.0000000000000215","volume":"23","author":"KJ Norsworthy","year":"2016","unstructured":"Norsworthy, K. J. & Altman, J. K. Optimal treatment strategies for high-risk acute promyelocytic leukemia. Curr. Opin. Hematol. 23, 127\u2013136 (2016).","journal-title":"Curr. Opin. Hematol."},{"key":"2759_CR7","first-page":"11","volume":"5","author":"M Kojima","year":"2016","unstructured":"Kojima, M. et al. Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: a case report. Leuk. Res. Rep. 5, 11\u201313 (2016).","journal-title":"Leuk. Res. Rep."},{"key":"2759_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw278","volume":"109","author":"W Cai","year":"2017","unstructured":"Cai, W. et al. Wanted DEAD\/H or alive: helicases winding up in cancers. J. Natl Cancer Inst. 109, 1\u201315 (2017).","journal-title":"J. Natl Cancer Inst."},{"key":"2759_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.celrep.2014.05.019","volume":"7","author":"A Mazurek","year":"2014","unstructured":"Mazurek, A. et al. Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Cell Rep. 7, 1887\u20131899 (2014).","journal-title":"Cell Rep."},{"key":"2759_CR10","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1038\/onc.2012.482","volume":"32","author":"S Lin","year":"2013","unstructured":"Lin, S. et al. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia. Oncogene 32, 4845\u20134853 (2013).","journal-title":"Oncogene"},{"key":"2759_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.biologicals.2016.05.006","volume":"44","author":"R Misaki","year":"2016","unstructured":"Misaki, R. et al. Recombinant production and characterization of human anti-influenza virus monoclonal antibodies identified from hybridomas fused with human lymphocytes. Biologicals 44, 394\u2013402 (2016).","journal-title":"Biologicals"},{"key":"2759_CR12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1292\/jvms.18-0146","volume":"80","author":"P Soni","year":"2018","unstructured":"Soni, P. et al. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J. Vet. Med. Sci. 80, 1020\u20131024 (2018).","journal-title":"J. Vet. Med. Sci."},{"key":"2759_CR13","doi-asserted-by":"publisher","first-page":"13424","DOI":"10.3390\/molecules171113424","volume":"17","author":"H Chen","year":"2012","unstructured":"Chen, H. et al. NADPH oxidase-derived reactive oxygen species are involved in the HL-60 cell monocytic differentiation induced by isoliquiritigenin. Molecules 17, 13424\u201313438 (2012).","journal-title":"Molecules"},{"key":"2759_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20091488","volume":"207","author":"C Callens","year":"2010","unstructured":"Callens, C. et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J. Exp. Med. 207, 731\u2013750 (2010).","journal-title":"J. Exp. Med."},{"key":"2759_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cr.2013.75","volume":"23","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y., Choksi, S., Chen, K., Pobezinskaya, Y. & Linnoila, I. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 23, 898\u2013914 (2013).","journal-title":"Cell Res."},{"key":"2759_CR16","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/annonc\/mdw171","volume":"27","author":"L Cicconi","year":"2016","unstructured":"Cicconi, L. & Lo-Coco, F. Current management of newly diagnosed acute promyelocytic leukemia. Ann. Oncol. 27, 1474\u20131481 (2016).","journal-title":"Ann. Oncol."},{"key":"2759_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.482","volume":"8","author":"S Ling","year":"2017","unstructured":"Ling, S. et al. Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I. Cell Death Dis. 8, e3159 (2017).","journal-title":"Cell Death Dis."},{"key":"2759_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","volume":"187","author":"M Stahl","year":"2019","unstructured":"Stahl, M. & Tallman, M. S. Differentiation syndrome in acute promyelocytic leukaemia. Br. J. Haematol. 187, 157\u2013162 (2019).","journal-title":"Br. J. Haematol."},{"key":"2759_CR19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.autrev.2017.10.012","volume":"16","author":"J Wu","year":"2017","unstructured":"Wu, J. et al. The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. Autoimmun. Rev. 16, 1270\u20131281 (2017).","journal-title":"Autoimmun. Rev."},{"key":"2759_CR20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","volume":"77","author":"T Igusa","year":"2018","unstructured":"Igusa, T. et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann. Rheum. Dis. 77, 1179\u20131186 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2759_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00432-015-2032-0","volume":"142","author":"S Mao","year":"2016","unstructured":"Mao, S., Shen, H. & Zhang, J. Systemic lupus erythematosus and malignancies risk. J. Cancer Res. Clin. 142, 253\u2013262 (2016).","journal-title":"J. Cancer Res. Clin."},{"key":"2759_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2759_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus, R. et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377, 1331\u20131344 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2759_CR24","first-page":"85","volume":"1871","author":"RM Nyamao","year":"2019","unstructured":"Nyamao, R. M., Wu, J., Yu, L., Xiao, X. & Zhang, F. M. Roles of DDX5 in the tumorigenesis, proliferation, differentiation, metastasis and pathway regulation of human malignancies. BBA 1871, 85\u201398 (2019).","journal-title":"BBA"},{"key":"2759_CR25","first-page":"111","volume":"57","author":"NV Ponomartsev","year":"2015","unstructured":"Ponomartsev, N. V. & Enukashvily, N. E. The DDX5 protein is involved in cell proliferation and differentiation. Tsitologiia 57, 111\u2013118 (2015).","journal-title":"Tsitologiia"},{"key":"2759_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-018-0725-3","volume":"37","author":"M Sha","year":"2018","unstructured":"Sha, M. et al. Long non-coding RNA MIAT promotes gastric cancer growth and metastasis through regulation of miR-141\/DDX5 pathway. J. Exp. Clin. Cancer Res. 37, 58\u201370 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2759_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/cas.12755","volume":"106","author":"ZD Wang","year":"2015","unstructured":"Wang, Z. D. et al. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating \u03b2-catenin signaling pathway. Cancer Sci. 106, 1303\u20131312 (2015).","journal-title":"Cancer Sci."},{"key":"2759_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1189\/jlb.1207833","volume":"84","author":"A Moeenrezakhanlou","year":"2008","unstructured":"Moeenrezakhanlou, A., Shephard, L., Lam, L. & Reiner, N. E. Myeloid cell differentiation in response to calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein downstream of phosphatidylinositol 3-kinase. J. Leukoc. Biol. 84, 519\u2013528 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"2759_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1158\/1078-0432.CCR-15-0663","volume":"22","author":"R Wang","year":"2016","unstructured":"Wang, R., Xia, L., Gabrilove, J., Waxman, S. & Jing, Y. Sorafenib inhibition of Mcl-1 accelerates ATRA-induced apoptosis in differentiation-responsive AML cells. Clin. Cancer Res. 22, 1211\u20131221 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2759_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.leukres.2018.01.007","volume":"68","author":"A Amanzadeh","year":"2018","unstructured":"Amanzadeh, A. et al. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells. Leuk. Res. 68, 98\u2013104 (2018).","journal-title":"Leuk. Res."},{"key":"2759_CR31","first-page":"827","volume":"47","author":"P Chen","year":"2006","unstructured":"Chen, P. et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J. Nucl. Med. 47, 827\u2013836 (2006).","journal-title":"J. Nucl. Med."},{"key":"2759_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S1083-8791(03)00129-0","volume":"9","author":"H Duzkale","year":"2003","unstructured":"Duzkale, H. et al. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195\/rGel. Biol. Blood Marrow Transplant. 9, 364\u2013372 (2003).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2759_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.imbio.2012.07.015","volume":"217","author":"CM Karsten","year":"2012","unstructured":"Karsten, C. M. & Kohl, J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 217, 1067\u20131079 (2012).","journal-title":"Immunobiology"},{"key":"2759_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep12022","volume":"5","author":"RH Weisbart","year":"2015","unstructured":"Weisbart, R. H. et al. DNA-dependent targeting of cell nuclei by a lupus autoantibody. Sci. Rep. 5, 1\u20136 (2015).","journal-title":"Sci. Rep."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02759-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02759-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02759-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:49:00Z","timestamp":1760086140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02759-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["2759"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-02759-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"552"}}